| Literature DB >> 18043732 |
Lei Mao1, Claus Zabel, Marion Herrmann, Tobias Nolden, Florian Mertes, Laetitia Magnol, Caroline Chabert, Daniela Hartl, Yann Herault, Jean Maurice Delabar, Thomas Manke, Heinz Himmelbauer, Joachim Klose.
Abstract
Large numbers of protein expression changes are usually observed in mouse models for neurodegenerative diseases, even when only a single gene was mutated in each case. To study the effect of gene dose alterations on the cellular proteome, we carried out a proteomic investigation on murine embryonic stem cells that either overexpressed individual genes or displayed aneuploidy over a genomic region encompassing 14 genes. The number of variant proteins detected per cell line ranged between 70 and 110, and did not correlate with the number of modified genes. In cell lines with single gene mutations, up and down-regulated proteins were always in balance in comparison to parental cell lines regarding number as well as concentration of differentially expressed proteins. In contrast, dose alteration of 14 genes resulted in an unequal number of up and down-regulated proteins, though the balance was kept at the level of protein concentration. We propose that the observed protein changes might partially be explained by a proteomic network response. Hence, we hypothesize the existence of a class of "balancer" proteins within the proteomic network, defined as proteins that buffer or cushion a system, and thus oppose multiple system disturbances. Through database queries and resilience analysis of the protein interaction network, we found that potential balancer proteins are of high cellular abundance, possess a low number of direct interaction partners, and show great allelic variation. Moreover, balancer proteins contribute more heavily to the network entropy, and thus are of high importance in terms of system resilience. We propose that the "elasticity" of the proteomic regulatory network mediated by balancer proteins may compensate for changes that occur under diseased conditions.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18043732 PMCID: PMC2077926 DOI: 10.1371/journal.pone.0001218
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Representative protein expression pattern of mouse embryonic cell lines as revealed by large-gel 2D-electrophoresis.
Over 5500 proteins (including protein isoforms) were resolved on a single gel. Highlighted spots correspond to spot ID of candidate balancer proteins detailed in Table 2.
Number of quantitatively variant proteins in six transgenic mouse embryonic stem cell lines.
| Quantitative changes | Number of variant proteins in different transgenic cell lines | |||||
| mES_14_Mono | mES_14_Tris | mES_Dopey2_Tris | mES_Dyrk1a_Tris | mES_hAPP | mES_Snca | |
|
| 44 | 44 | 37 | 41 | 46 | 52 |
|
| 62 | 26 | 45 | 37 | 47 | 57 |
|
| 106 | 70 | 82 | 78 | 93 | 109 |
The segment from mouse chromosome 17 includes 14 genes.
Proteins changed in more than three transgenic ES cell lines (proposed balancer proteins).
| Spot ID | Protein Name | Gene Symbol | Behavior |
| B125 | aminolevulinate, delta-, dehydratase |
| 3 ↑, 2↓ |
| S37 | albumin |
| 1 ↑, 3↓ |
| B40 | ATPase, H+ transporting, lysosomal V1 subunit C1 |
| always up |
| S34 | BAT2 domain containing 1 |
| always down |
| B96 | carbonic anhydrase 2 |
| 1 ↑, 3↓ |
| B476 | calcium response factor |
| 2 ↑,2↓ |
| B72 | coiled-coil domain containing 25 |
| always up |
| B178 | eukaryotic translation elongation factor 1 alpha 1 |
| 1 ↑, 3↓ |
| B70 | enolase 1, alpha non-neuron |
| always up |
| S10 | fatty acid binding protein 3, muscle and heart |
| 2 ↑, 4↓ |
| B110 | guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 |
| 1 ↑, 3↓ |
| S98 | golgi autoantigen, golgin subfamily b, macrogolgin 1 |
| 1 ↑, 4↓ |
| B175 | glutamate oxaloacetate transaminase 2, mitochondrial |
| 3 ↑, 1↓ |
| B121 | glyoxylate reductase/hydroxypyruvate reductase |
| 3 ↑, 2↓ |
| S160 | histone cell cycle regulation defective interacting protein 5 |
| 2 ↑, 2↓ |
| B154 | heterogeneous nuclear ribonucleoprotein A2/B1 |
| 4 ↑, 1↓ |
| B134 | LIM and SH3 protein 1 |
| 2 ↑, 4↓ |
| B123 | mitochondrial ribosomal protein L39 |
| 3 ↑, 2↓ |
| S38 | nucleophosmin 1 |
| 1 ↑, 3↓ |
| B62 | nudix (nucleoside diphosphate linked moiety X)-type motif 16-like 1 |
| always up |
| B475 | polyribonucleotide nucleotidyltransferase 1 |
| 1 ↑, 3↓ |
| S238 | pyrophosphatase (inorganic) 1 |
| 2 ↑, 2↓ |
| B45 | PPAR-alpha interacting complex protein 285 |
| 4 ↑, 1↓ |
| S557 | proteasome (prosome, macropain) subunit, beta type 6 |
| always down |
| B77 | proteasome (prosome, macropain) subunit, beta type 7 |
| always up |
| S90 | proteasome (prosome, macropain) 28 subunit, alpha |
| 1 ↑, 3↓ |
| B43 | RAN binding protein 5 |
| always up |
| S6 | S100 calcium binding protein A11 (calgizzarin) |
| always up |
| B203 | serine (or cysteine) peptidase inhibitor, clade H, member 1 |
| 1 ↑, 3↓ |
| B422 | single-stranded DNA binding protein 1 |
| 2 ↑, 2↓ |
| B50 | transgelin |
| 1 ↑, 3↓ |
| B124 | transaldolase 1 |
| 3 ↑, 2↓ |
| S32 | transcription elongation factor B (SIII), polypeptide 2 |
| always down |
| S204 | thimet oligopeptidase 1 |
| 1 ↑, 3↓ |
| S100 | tropomyosin 1, alpha |
| 1 ↑, 4↓ |
| S395 | Thioredoxin-like 2 |
| 2 ↑, 2↓ |
| S4 | Thioredoxin 1 |
| 2 ↑, 2↓ |
| S99 | Thioredoxin-related protein |
| 2 ↑, 2↓ |
Figure 2Proteins that showed altered expression in transgenic ES cell lines.
(A) Number of altered proteins in each transgenic cell line, expressed as percentile of total number of altered proteins. (B) Amount of proteins that underwent altered expression in each cell line, represented as percent of total spot volume that was up or down-regulated in transgenic cell lines. Dose alteration of 14 genes could no longer be balanced by an equivalent number of variant proteins. However, a balance remained at the level of protein concentration.
Figure 3Comparison of observed number of co-changed proteins against a theoretical calculation of co-changed proteins across six different transgenic cell lines.
It was assumed that a total of 800 protein spots were investigated, among which 10% of the proteins change in their expression profile. This comparison shows that the occurrence of the same protein alteration in more than three cell lines is unlikely to be coincidental.
Comparison of protein properties of balancer and cell line-specific proteins.
| Protein properties | Balancers | Cell line-specific proteins | p-value |
|
| 47.2±42.5 | 48.3±47.3 | 0.906 |
|
| 6.52±1.68 | 6.98±1.71 | 0.14 |
|
| 41.3±12.8 | 41.8±11.2 | 0.81 |
|
| 79.7±14.2 | 77.7±16.8 | 0.51 |
|
| −0.449±0.337 | −0.444±0.357 | 0.94 |
|
|
|
|
|
|
|
|
|
|
|
| 29.5±40.1 | 30.6±58.7 | 0.46 |
|
| 2.7±4.7 | 1.9±4.9 | 0.53 |
|
| 1.0±2.3 | 1.9±4.9 | 0.76 |
|
| 18.8±31.3 | 20.5±48.1 | 0.43 |
|
| 1.3±3.1 | 1.4±0.5 | 0.12 |
|
|
|
|
|
|
| 2.1±4.6 | 1.1±3.2 | 0.0855 |
|
| 2.6±5.4 | 3.2±5.3 | 0.89 |
|
|
|
|
|
Values in bold indicate significant difference between balancer and cell line-specific proteins
Interval up to a position 2000 bp upstream of the transcription start site
Interval from polyadenylation site to a position 2000 bp downstream
Standard errors not shown since the distributions are tend to be screwed.
Figure 4Cumulative fraction plots of “balancer”-“cell line-specific protein” comparison.
(A) Entropic contribution.; (B) Number of direct protein interaction partners. Compared to cell line-specific proteins, balancers possess significantly higher values of entropic contribution and a low number of direct interaction partners.
GO-terms enriched among balancer proteins detected in the proteome of mouse ES cells.
| GO-ID | Count | Total | p-Value | GO-term | Category |
| GO:0009056 | 7 | 877 | 0.002 | catabolism | BP |
| GO:0006091 | 7 | 1028 | 0.003 | generation of precursor metabolites and energy | BP |
| GO:0030508 | 2 | 5 | 0.001 | thiol-disulfide exchange intermediate activity | MF |
| GO:0015035 | 3 | 73 | 0.003 | protein disulfide oxidoreductase activity | MF |
| GO:0016836 | 3 | 81 | 0.003 | hydro-lyase activity | MF |
| GO:0016835 | 3 | 92 | 0.004 | carbon-oxygen lyase activity | MF |
| GO:0015036 | 3 | 96 | 0.004 | disulfide oxidoreductase activity | MF |
| GO:0009055 | 4 | 289 | 0.007 | electron carrier activity | MF |
Number of balancer proteins bearing this GO-term.
Total number of proteins in the human GOA database annotated with this GO-term.
BP: biological process; MF: Molecular function.
Enriched GO-terms among cell line-specific proteins detected in the proteome of mouse embryonic stem cells.
| GO-ID | Count | Total | p-Value | GO-term | Category |
| GO:0043170 | 41 | 7475 | 7.85E-07 | macromolecule metabolism | BP |
| GO:0006396 | 11 | 503 | 3.49E-06 | RNA processing | BP |
| GO:0044238 | 53 | 11859 | 3.83E-06 | primary metabolism | BP |
| GO:0016070 | 12 | 662 | 4.71E-06 | RNA metabolism | BP |
| GO:0008152 | 57 | 13425 | 4.76E-06 | metabolism | BP |
| GO:0008614 | 2 | 2 | 1.72E-04 | pyridoxine metabolism | BP |
| GO:0008615 | 2 | 2 | 1.72E-04 | pyridoxine biosynthesis | BP |
| GO:0042816 | 2 | 2 | 1.72E-04 | vitamin B6 metabolism | BP |
| GO:0042819 | 2 | 2 | 1.72E-04 | vitamin B6 biosynthesis | BP |
| GO:0043283 | 24 | 4377 | 0.001 | biopolymer metabolism | BP |
| GO:0006139 | 27 | 5422 | 0.002 | nucleobase, nucleoside, nucleotide and nucleic acid metabolism | BP |
| GO:0016071 | 6 | 292 | 0.002 | mRNA metabolism | BP |
| GO:0006397 | 5 | 243 | 0.006 | mRNA processing | BP |
| GO:0006511 | 5 | 248 | 0.006 | ubiquitin-dependent protein catabolism | BP |
| GO:0019941 | 5 | 248 | 0.006 | modification-dependent protein catabolism | BP |
| GO:0043632 | 5 | 248 | 0.006 | modification-dependent macromolecule catabolism | BP |
| GO:0044260 | 25 | 5232 | 0.007 | cellular macromolecule metabolism | BP |
| GO:0019538 | 26 | 5543 | 0.007 | protein metabolism | BP |
| GO:0000375 | 4 | 148 | 0.007 | RNA splicing, via transesterification reactions | BP |
| GO:0000377 | 4 | 148 | 0.007 | RNA splicing, via transesterification | BP |
| GO:0000398 | 4 | 148 | 0.007 | nuclear mRNA splicing, via spliceosome | BP |
| GO:0006564 | 2 | 16 | 0.009 | L-serine biosynthesis | BP |
| GO:0030530 | 2 | 16 | 0.009 | heterogeneous nuclear ribonucleoprotein | BP |
| GO:0044257 | 5 | 288 | 0.009 | cellular protein catabolism | BP |
| GO:0051603 | 5 | 287 | 0.009 | proteolysis during cellular protein catabolism | BP |
| GO:0003723 | 14 | 930 | 3.83E-06 | RNA binding | MF |
| GO:0008266 | 2 | 2 | 1.72E-04 | poly(U) binding | MF |
| GO:0016018 | 2 | 6 | 0.002 | cyclosporin A binding | MF |
| GO:0050662 | 5 | 193 | 0.002 | coenzyme binding | MF |
| GO:0000166 | 21 | 3851 | 0.003 | nucleotide binding | MF |
| GO:0048037 | 5 | 220 | 0.004 | cofactor binding | MF |
| GO:0003727 | 2 | 12 | 0.006 | single-stranded RNA binding | MF |
| GO:0008144 | 2 | 17 | 0.010 | drug binding | MF |
Number of cell line-specific proteins bearing this GO-term.
Total number of proteins in the human GOA database annotated with this GO-term.
BP: biological process; MF: Molecular function.
Figure 5A protein-protein interaction subgraph showing the proteasome subunits, where nodes denote proteins and the edges describe protein-protein interaction.
Two local hub proteins of this subgraph (Psma2 and Psma3) belong to cell line-specific proteins, while a candidate balancer protein (Psmb6) represents a connection between these two modules (see discussion for details). This supports our assumption that balancer proteins could be connective hubs between different modules. Protein marked in green: Psma2; yellow: Psmb6; magenta: Psma3.